// App-Quantinova.ai

: FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma

Researchers

Presenter

  • Matthew J. Maurer

Principal Investigators

  • Christopher R. Flowers

  • Lasse Hjort Jakobsen

  • Diego Villa

  • Caroline E. Weibull

  • Elliot J. Cahn

  • Alexandra Smith

  • Herve Ghesquieres

  • Robert Kridel

  • Maher Gandhi

  • Chan Y. Cheah

  • Eliza Hawkes

  • John F. Seymour

  • Ciara L. Freeman

  • Michael Roost Clausen

  • Bjorn E Wahlin

  • Jonathan W. Friedberg

  • Carla Casulo

  • Thomas M. Habermann

  • Yucai Wang

  • Loretta J. Nastoupil

  • Peter de Nully Brown

  • David Belada

  • Andrea Janikova

  • Heidi Mocikova

  • Tomas Furst

  • Richard Burack

  • Peter Martin

  • Jonathon B. Cohen

  • Izidore S. Lossos

  • Brad S. Kahl

  • Brian K. Link

  • Karin E. Smedby

  • Laurie H. Sehn

  • Marek Trneny

  • Tarec Christoffer Christoffer El-Galaly

  • James R. Cerhan

Medical Centers

  • Department of Lymphoma and Myeloma, MD ANDERSON CANCER CENTER, HOUSTON, TX

  • Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

  • Department of Mathematical Analysis and Applications of Mathematics, Faculty of Science, Palacky University, Olomouc, Czech Republic

  • Department of Internal Medicine, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic

  • University Health Network, Princess Margaret Cancer Center, Toronto, Canada

  • The University of Texas MD Anderson Cancer Center, Houston, TX

  • Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY

  • KAROLINSKA INSTITUTE, Stockholm, Sweden

  • Centre for Lymphoid Cancer, BC Cancer, Vancouver, Canada

  • Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY

  • Department of Hematology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

  • Department of Hematology and Oncology, Faculty of Medicine, Masaryk University and University Hospital, Brno, Czech Republic

  • Department of Hematology, Lyon Sud University Hospital/Hospices Civils de Lyon, Pierre Benite, France

  • Peter MacCallum Cancer Centre, MELBOURNE, Australia

  • Department of Pathology and Laboratory Medicine/Hematopathology, University of Rochester Medical Center, Rochester, NY

  • Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

  • st Department of Internal Medicine - Hematology, General Hospital, Charles University, Prague, Czech Republic

  • Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL

  • Department of Hematology and Aalborg Hospital Science and Innovation Center (AHSIC), Aalborg University Hospital, Aalborg, Denmark

  • Department of Haematology, Vejle Hospital, Vejle, Denmark

  • Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN

  • Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

  • Department of Hematology and Medical Oncology, Emory University, Atlanta, GA

  • Centre for Lymphoid Cancer, Department of Medical Oncology, BC Cancer and The University of British Columbia, Vancouver, Canada

  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN

  • Department of Haematology, Aalborg University Hospital, Aalborg, Denmark

  • Department of Haematology, Princess Alexandra Hospital, Mater Research University of Queensland, Brisbane, Australia

  • Division of Oncology, Washington University School of Medicine, St. Louis, MO

  • Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia

  • Charles University, Faculty of Medicine, Prague, Czech Republic

  • Department of Hemato-Oncology, Faculty of Medicine and Dentistry, University Hospital In Olomouc, Olomouc, Czech Republic

  • Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA

  • Department of Clinical Haematology, Austin Health, Heidelberg, Australia

Locations

  • United States

  • Denmark

  • Sweden

  • Australia

  • Czech Republic

  • France

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Follicular lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Bendamustine

Outcome

  • N/A

Study Design

  • Observational

  • Multinational

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved